JP4526384B2 - カンナビス活性成分の投与のためのフィルム型粘着性投与形態 - Google Patents
カンナビス活性成分の投与のためのフィルム型粘着性投与形態 Download PDFInfo
- Publication number
- JP4526384B2 JP4526384B2 JP2004512706A JP2004512706A JP4526384B2 JP 4526384 B2 JP4526384 B2 JP 4526384B2 JP 2004512706 A JP2004512706 A JP 2004512706A JP 2004512706 A JP2004512706 A JP 2004512706A JP 4526384 B2 JP4526384 B2 JP 4526384B2
- Authority
- JP
- Japan
- Prior art keywords
- cannabis
- group
- formulation
- tetrahydrocannabinol
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
カンナビス抽出物は、薬理学的に活性な成分として、テトラヒドロカンナビノール(主にΔ−9−テトラヒドロカンナビノール、小さい割合でΔ−8−テトラヒドロカンナビノール)、カンナビジオール、カンナビノールおよびカンナビクロメンを含有する。これらの活性剤はまた、カンナビノイドとも呼ばれる(リスト“The Merck Index”12版、1996年、285頁、No.1794の他に1573頁、No.9349を参照。)。
−前記投与形態の使用では、活性剤の吸収が胃腸管内で起こるため、作用の開始時間が遅れてしまう。このことは、一般的に早急な作用の開始が求められる、とりわけ前記した兆候(例えば、苦痛の治療)に関して不利益である。
−カンナビス剤は、胃および腸の通過中に、酸および酵素の影響下で、少なくとも部分的に分解および不活性化され、その結果、投与量の一部分のみが吸収され、全身で有効になる。
−これに関して、望まない血漿ピーク値が生じることがあり、それはしばしば副作用の原因である。
−加えて、経口投与後、肝臓を最初に通過する間に、かなりの割合の活性物質が、すでに代謝される(“初回通過効果”)。
この目的は、請求項1に記載の、カンナビス活性剤の群から、少なくとも1種の活性剤の内容物を有する、フィルム型粘着性投与形態を有する製剤により達成され、さらに好ましい態様は下位クレームに記載されている。
さらにその目的は、病気および症状の処置において、本発明のフィルム型粘着性投与形態の使用により達成される。
好ましい態様によれば、本発明の製剤は、カンナビス抽出物またはカンナビスオイルを、好ましくは0.5〜50重量%、とりわけ好ましくは1〜30重量%の量で含有する。薬学的に許容できるカンナビス抽出物またはカンナビスオイルの製造工程は、当業者に既知である。
それぞれの製剤は、好ましくは、0.5〜20mg、とりわけ好ましくは1〜10mgの活性剤、例えばテトラヒドロカンナビノールを含有する。
任意に、本発明の製剤は、以下の群からの1種または2種以上の添加剤を含有することができる:充填剤、着色剤、フレーバー、芳香族化合物、におい物質、乳化剤、可塑剤、甘味料、防腐剤、浸透増強物質、pH調整剤、および酸化防止剤。この目的に好適な物質は、基本的に当業者には既知である。
例えば、メントール、ユーカリプトール、リモネン、フェニルエタノール、カンフェン、ピネン、n−ブチルフタリドまたはシネオールなどの風味をつける芳香族化合物の他に、ユーカリ油、タイム油、サリチル酸メチル、テレビン油、カミツレ油、エチルバニリン、6−メチルクマリン、シトロネロール、および酢酸n−ブチルエステルを含む群からのフレーバーおよび芳香族化合物が、とりわけ好適である。
それらの厚さは総計で、好ましくは0.01〜2mmであり、特に好ましくは0.05〜0.5mmの範囲である。
異物感を避けるためには、層の厚さはできるだけ薄くすべきである(好ましくは0.2mmより薄く)。
Claims (12)
- 口腔粘膜への投与のためのフィルム型の粘膜粘着性投与製剤であって、活性物質貯蔵体として機能し、かつ粘膜粘着性特性を有するポリマーマトリックスを有し、該ポリマーマトリックスが、
− テトラヒドロカンナビノール、カンナビノール、カンナビジオールおよびカンナビクロメンからなる群より選択される1または2以上のカンナビノイド活性剤またはカンナビス抽出物またはカンナビスオイルの群から選択される少なくとも1種の活性剤、
− フレーバー、におい物質および芳香族化合物からなる群から選択される1または2以上の物質
を含有し、層の厚さが0.01〜0.5mmである、前記製剤。 - ポリマーマトリックスが、水溶性および/または水性媒体中で膨潤性である1種または2種以上のポリマーを含有し、該ポリマーが、好ましくは、スターチおよびスターチ誘導体、デキストラン、カルボキシメチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルエチルセルロース、カルボキシメチルセルロースナトリウム、エチルセルロースまたはプロピルセルロース、ポリアクリル酸、ポリアクリレート、ポリビニルピロリドン、ポリエチレンオキシドポリマー、ポリアクリルアミド、ポリエチレングリコール、ゼラチン、コラーゲン、アルギネート、ペクチン、プルラン、トラガカント、キトサン、アルギン酸、アラビノガラクタン、ガラクトマンナン、寒天、アガロース、カラギーナン、および天然ゴムからなる群から選択され、該ポリマー部が、5〜95重量%であることを特徴とする、請求項1に記載の製剤。
- カンナビス抽出物またはカンナビスオイルを、0.5〜50重量%の量で含有することを特徴とする、請求項1または2に記載の製剤。
- フレーバー、におい物質および芳香族化合物の群からの1種または2種以上の物質が、メントール、ユーカリプトール、リモネン、フェニルエタノール、カンフェン、ピネン、n−ブチルフタリドまたはシネオールなどの風味をつける芳香族化合物の他に、ユーカリ油、タイム油、サリチル酸メチル、テレビン油、カミツレ油、エチルバニリン、6−メチルクマリン、シトロネロール、および酢酸n−ブチルエステルを含む群から選択されることを特徴とする、請求項1〜3のいずれかに記載の製剤。
- 充填剤、着色剤、乳化剤、可塑剤、甘味料、防腐剤、pH調整剤、浸透増強物質、および酸化防止剤の群からの1種または2種以上の不活性成分を含有することを特徴とする、請求項1〜4のいずれかに記載の製剤。
- 活性剤内容物を有する少なくとも1層を伴う、多層構造を有することを特徴とする、請求項1〜5のいずれかに記載の製剤。
- カンナビス抽出物またはカンナビスオイルが、テトラヒドロカンナビノール、カンナビノール、カンナビジオールおよびカンナビクロメンからなる群より選択される1または2以上のカンナビノイド活性成分を含むことを特徴とする、請求項1〜6のいずれかに記載の製剤。
- 舌下または頬側への適用のための、請求項1〜7のいずれかに記載の製剤。
- 1または2以上のカンナビノイド活性剤が0.5〜10重量%の量で含有する、請求1に記載の製剤。
- テトラヒドロカンナビノールを含むことを特徴とする、請求項1に記載の製剤。
- テトラヒドロカンナビノールがR−(6a,10a)−Δ−9−テトラヒドロカンナビノールであることを特徴とする、請求項10に記載の製剤。
- 0.5〜20mgの活性剤を含むことを特徴とする、請求項1に記載の製剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10226494A DE10226494A1 (de) | 2002-06-14 | 2002-06-14 | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
PCT/EP2003/004807 WO2003105800A2 (de) | 2002-06-14 | 2003-05-08 | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005533780A JP2005533780A (ja) | 2005-11-10 |
JP2005533780A5 JP2005533780A5 (ja) | 2006-01-26 |
JP4526384B2 true JP4526384B2 (ja) | 2010-08-18 |
Family
ID=29719057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004512706A Expired - Fee Related JP4526384B2 (ja) | 2002-06-14 | 2003-05-08 | カンナビス活性成分の投与のためのフィルム型粘着性投与形態 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20060039959A1 (ja) |
EP (1) | EP1513494A2 (ja) |
JP (1) | JP4526384B2 (ja) |
CN (1) | CN1658840A (ja) |
AU (1) | AU2003227735B2 (ja) |
BR (1) | BR0311867A (ja) |
CA (1) | CA2489106A1 (ja) |
DE (1) | DE10226494A1 (ja) |
IL (1) | IL165744A0 (ja) |
RU (1) | RU2324476C2 (ja) |
WO (1) | WO2003105800A2 (ja) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US9066847B2 (en) * | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US9289583B2 (en) * | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
DE102006027791A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | AchE-NMDA-Kombinationswafer |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
US8242178B2 (en) * | 2007-06-18 | 2012-08-14 | University Of South Carolina | Use of cannabidiol in the treatment of autoimmune hepatitis |
GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
BRPI0924915A2 (pt) | 2009-04-01 | 2015-07-07 | Colgate Palmolive Co | Método e composição para fornecer benefícios para o cuidado da saúde oral e sistêmica intensificados e método e composição para regular para cima ou regular para baixo os metabólicos da doença periodontal. |
GB2471523A (en) * | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途 |
WO2011147455A1 (en) * | 2010-05-27 | 2011-12-01 | Symrise Ag | Flavoring substance-included compounds |
RU2453559C1 (ru) | 2010-10-11 | 2012-06-20 | Общество С Ограниченной Ответственностью "Ниармедик Плюс" | Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями |
GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
EP4137142A1 (en) | 2013-03-14 | 2023-02-22 | Purple Mundo, Inc. | Bioactive concentrates and uses thereof |
WO2015069763A2 (en) * | 2013-11-05 | 2015-05-14 | First Watersign Llc | Sublingual cannabis dosage form and methods of making and using the same |
US11033493B2 (en) * | 2013-12-02 | 2021-06-15 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
US10272038B2 (en) * | 2013-12-02 | 2019-04-30 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
US10821240B2 (en) | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
US9380813B2 (en) | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
US9186386B2 (en) | 2014-04-17 | 2015-11-17 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
US10392178B2 (en) * | 2014-04-21 | 2019-08-27 | Zen Potion, Inc. | Preparing beverages containing cannabinoids using beverage containers with polymer matrices |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
EP3160451B1 (en) * | 2014-06-27 | 2021-04-07 | Farm To Farma, Inc. | Buccal and sublingual cannabinoid formulations and method of making the same |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
WO2016092539A1 (en) * | 2014-12-07 | 2016-06-16 | One World Cannabis Ltd | Use of cannabis to treat migraine |
WO2016106329A1 (en) | 2014-12-23 | 2016-06-30 | Acelrx Pharmaceuticals, Inc. | Systems, devices and methods for dispensing oral transmucosal dosage forms |
US20160213027A1 (en) * | 2015-01-21 | 2016-07-28 | George Maniatakos | Pet food additive |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
MX2017016787A (es) * | 2015-06-22 | 2018-08-15 | Johnson & Johnson Consumer Inc | Método para proporcionar un beneficioa la piel. |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
US20170112188A1 (en) * | 2015-10-22 | 2017-04-27 | John Ostrander | Wrapper For Enclosing Smokable Substances |
US20170188616A1 (en) * | 2015-12-17 | 2017-07-06 | Therabis, Llc | Cannabinoid-enriched supplement |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
EP3538078A4 (en) * | 2016-11-11 | 2020-07-08 | Bennes, Inc. | FORMULATIONS FOR EFFICIENT CANNABINOID DELIVERY |
CA3040014A1 (en) | 2016-11-15 | 2018-05-24 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
CN109394836A (zh) * | 2017-08-18 | 2019-03-01 | 汉义生物科技(北京)有限公司 | 一种预防和/或缓解痛经的大麻纤维及其在卫生用品中的应用 |
CN109498606A (zh) * | 2017-09-15 | 2019-03-22 | 汉义生物科技(北京)有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
US20190125660A1 (en) * | 2017-10-31 | 2019-05-02 | Calitas Therapeutics, Inc | Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
CN108743571B (zh) * | 2018-08-07 | 2020-10-02 | 云南汉木森生物科技有限责任公司 | 预防、治疗癫痫的药物组合物及其制备方法 |
FR3084837B1 (fr) | 2018-08-10 | 2021-10-29 | Urgo Rech Innovation Et Developpement | Composition filmogene mucoadhesive et son utilisation pour le traitement des douleurs liees aux poussees dentaires |
US11602504B2 (en) * | 2018-11-05 | 2023-03-14 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
DE102019100483A1 (de) * | 2019-01-10 | 2020-07-16 | Lts Lohmann Therapie-Systeme Ag | Oraler Dünnfilm |
CN110200953B (zh) * | 2019-06-15 | 2022-02-08 | 汉义生物科技(北京)有限公司 | 大麻素在制备吸入给药药物中的应用 |
US11497249B2 (en) | 2019-09-16 | 2022-11-15 | Vapor Cartridge Technology Llc | Drug delivery system with stackable substrates |
US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
EP3808341A1 (de) * | 2019-10-16 | 2021-04-21 | ADD Advanced Drug Delivery Technologies, Ltd. | Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen |
CN111228241B (zh) * | 2020-01-16 | 2023-08-04 | 全越 | 一种成膜组合物及其应用 |
CN111150729B (zh) * | 2020-01-16 | 2021-02-12 | 全越 | 一种成膜组合物及其应用 |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
US11986008B2 (en) | 2021-09-01 | 2024-05-21 | David Addington | Method of processing cannabis |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2703795A (en) * | 1994-06-23 | 1996-01-19 | Procter & Gamble Company, The | Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine |
US6328992B1 (en) * | 1997-03-03 | 2001-12-11 | Lawrence L. Brooke | Cannabinoid patch and method for cannabis transdermal delivery |
US5989535A (en) * | 1997-08-15 | 1999-11-23 | Soma Technologies | Polymeric bioadhesive emulsions and suspensions and methods of treatment |
EP1021204B1 (en) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US6509005B1 (en) * | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
US6319510B1 (en) * | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
CN1258359C (zh) * | 2000-03-09 | 2006-06-07 | Gw药品有限公司 | 药物组合物 |
DE10051427C1 (de) * | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
US6730330B2 (en) * | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
CZ306277B6 (cs) * | 2001-02-14 | 2016-11-09 | Gw Pharma Limited | Pumpičkou aktivovaná kapalná sprejová formulace |
US20030017216A1 (en) * | 2001-07-23 | 2003-01-23 | Schmidt Robert Gustav | Isolation of herbal and cannabinoid medicinal extracts |
EP1539069A4 (en) * | 2002-05-31 | 2007-11-14 | Univ Mississippi | TRANSMUCOSAL DELIVERY OF CANNABINOIDS |
-
2002
- 2002-06-14 DE DE10226494A patent/DE10226494A1/de not_active Withdrawn
-
2003
- 2003-05-08 JP JP2004512706A patent/JP4526384B2/ja not_active Expired - Fee Related
- 2003-05-08 AU AU2003227735A patent/AU2003227735B2/en not_active Ceased
- 2003-05-08 BR BR0311867-3A patent/BR0311867A/pt not_active IP Right Cessation
- 2003-05-08 RU RU2005100953/15A patent/RU2324476C2/ru not_active IP Right Cessation
- 2003-05-08 EP EP03725174A patent/EP1513494A2/de not_active Withdrawn
- 2003-05-08 CA CA002489106A patent/CA2489106A1/en not_active Abandoned
- 2003-05-08 WO PCT/EP2003/004807 patent/WO2003105800A2/de active Application Filing
- 2003-05-08 US US10/517,849 patent/US20060039959A1/en not_active Abandoned
- 2003-05-08 CN CN038137291A patent/CN1658840A/zh active Pending
-
2004
- 2004-12-13 IL IL16574404A patent/IL165744A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
RU2005100953A (ru) | 2005-09-20 |
CN1658840A (zh) | 2005-08-24 |
AU2003227735B2 (en) | 2009-07-09 |
EP1513494A2 (de) | 2005-03-16 |
BR0311867A (pt) | 2005-03-15 |
WO2003105800A3 (de) | 2004-12-09 |
IL165744A0 (en) | 2006-01-15 |
US20060039959A1 (en) | 2006-02-23 |
AU2003227735A1 (en) | 2003-12-31 |
JP2005533780A (ja) | 2005-11-10 |
DE10226494A1 (de) | 2004-01-08 |
RU2324476C2 (ru) | 2008-05-20 |
CA2489106A1 (en) | 2003-12-24 |
WO2003105800A2 (de) | 2003-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4526384B2 (ja) | カンナビス活性成分の投与のためのフィルム型粘着性投与形態 | |
KR101720546B1 (ko) | 구강 삽입용 투여 제형 | |
JP2005533780A5 (ja) | ||
JP2002534463A (ja) | 改善された薬剤活性体投与性をもつ組成物 | |
MXPA02003312A (es) | Composiciones que tienen estabilidad mejorada. | |
JP2010504312A (ja) | 活性成分の経粘膜投与のためのガレノス的方式 | |
KR20090020561A (ko) | 필름 피복된 고체 투여 형태 | |
US5702723A (en) | Multi-stage delivery system for ingestible medications or nutrients | |
US20120015021A1 (en) | Anti-appetite adhesive compositions | |
Rathod et al. | Medicated lozenges as an easy to use dosage form | |
CA3151070A1 (en) | Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids | |
Gijare et al. | Orodispersible Films: A systematic patent review | |
KR20060037279A (ko) | 점막 자극이 감소된 경점막 투여 형태 | |
US20090203670A1 (en) | Combination Antidepressants Wafer | |
US20090291123A1 (en) | Opioid Combination Wafer | |
KR102055859B1 (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
AU2004273574B2 (en) | Buccal formulations of galanthamine and uses thereof | |
KR20050021003A (ko) | 대마 활성 성분의 투여용 필름 형상의 점막접착성 투여 제형 | |
US20080187589A1 (en) | Multi-modal delivery via transmucosal and gastro-intestinal absorption of antihistamines and symptom relief | |
JP2011511823A (ja) | エストラジオール含有薬物の送達システム | |
JP2007512270A (ja) | デオキシペガニンの経口製剤およびそれらの使用 | |
WO2012146314A1 (en) | Thin gelatin capsules for rapid drug release in the mouth | |
AU2022259844B1 (en) | Pharmaceutical Combinations for Treatment | |
Pasha | Formulation and Evaluation of Orodispersible Fast Release Films of Non Sedative Long Acting H-1 Anti-Histamine Loratadine | |
Sain et al. | SUBLINGUAL TABLET-NOVEL DRUG DELIVERY SYSTEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051128 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090721 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091021 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091028 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091124 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100409 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100518 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100601 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130611 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |